INNOCARE - An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section

does not make any representation about the accuracy or completeness of this announcement and expressly disclaims any liability arising out of or in connection with all or any part of this announcement. We accept no liability for any loss caused by reliance on such content.

InnoCare Pharma Limited Nuocheng Jianhua Pharmaceutical Co., Ltd.

(Incorporated in the Cayman Islands with limited liability) (Stock code: 9969)

Overseas regulatory announcement

This announcement is made by InnoCheng Jianhua Pharmaceutical Co., Ltd. (the "Company") pursuant to the Securities and Exchange Commission of The Stock Exchange of Hong Kong Limited.

Made in accordance with Rule 13.10B of the Securities Listing Rules.

This is to set forth the "Announcement on Board Resolutions" and "About 2023" published by the Company on the website of the Shanghai Stock Exchange. The third vesting period of the initial grant portion of the Science and Technology Innovation Board restricted stock incentive plan and the second vesting period of the reserved grant portion Announcement on Compliance with vesting conditions during the vesting period", "Announcement on the invalidation of some restricted shares that have been granted but have not vested yet" "Announcement on the Use of Idle Own Funds for Cash Management", "Announcement on the Use of Idle Own Funds for Cash Management", "Announcement on the 2026 Science and Technology Innovation Self-examination report on the insider trading of the company's stocks under the restricted stock incentive plan, "2026

List of first grant incentive objects of the Science and Technology Innovation Board Restricted Stock Incentive Plan (as of the date of first grant)", "The Compensation Committee of the Board of Directors Regarding the Initial Grant of Part III of the 2023 Science and Technology Innovation Board Restricted Stock Incentive Plan" Verification Opinions on the Vesting Period and the Vesting List of the Reserved Part for the Second Vesting Period", "Board of Directors Remuneration" The Committee’s verification of the list of first-time incentive recipients under the 2026 Science and Technology Innovation Board Restricted Stock Incentive Plan Opinions", "Shanghai Fangda Law Firm's Opinions on InnoCare Pharma Limited) 2025 Annual General Meeting of Shareholders”, “Shanghai Fangda Law Firm’s Legal Opinion on No.

InnoCare Pharma Limited 2023 Science and Technology Innovation Board Restricted Stock Incentive Plan The third vesting period of the planned initial grant part and the second vesting period of the reserved grant part vesting condition achievements and Legal Opinions on Matters Related to the Invalidation of Partial Restricted Stocks" and "Shanghai Fangda Law Firm's Legal Opinions on InnoCare Pharma Limited 2026 Science and Technology Innovation Board Restricted Stock Incentive "Legal Opinion on Matters Related to the First Grant of the Plan".

By order of the board of directors

Nuocheng Jianhua Pharmaceutical Co., Ltd. Chairman and Executive Director Dr. Cui Jisong

Hong Kong, June 16, 2026

As at the date of this announcement, the Board of Directors includes Dr. Cui Jisong, Chairman and Executive Director; Dr. Zhao Renbin, Executive Director; Non-executive Directors

Dr. Shi Yigong and Mr. Xie Ronggang; and independent non-executive directors Ms. Hu Lan, Dr. Dong Dandan and Professor Guan Kunliang.

Remuneration Committee of the Board of Directors of InnoCheng Jianhua Pharmaceutical Co., Ltd.

About the 2019 Science and Technology Innovation Board Restricted Stock Incentive Plan 2023

The third vesting period of the initial grant portion and the second vesting period of the reserved grant portion

Verification opinions on the vesting list during the vesting period

The Remuneration Committee of the Board of Directors of InnoCheng Jianhua Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") complies with the "China

Company Law of the People's Republic of China, Securities Law of the People's Republic of China, Equity Incentive Management Office of Listed Companies

Law" (hereinafter referred to as the "Administrative Measures"), "Shanghai Stock Exchange Science and Technology Innovation Board Stock Listing Rules"

(hereinafter referred to as the "Listing Rules"), "Self-discipline Supervision Guidelines for Companies Listed on the Science and Technology Innovation Board No. 4 - Shareholding

In accordance with the relevant provisions of relevant laws, regulations and normative documents such as "Disclosure of Rights Incentive Information", the restrictions on this restricted stock The third vesting period of the first vesting portion of the ticket incentive plan and the second vesting period of the reserved grant portion are eligible for vesting.

The list of incentive objects subject to the conditions was verified. After verification, it was found that the 134 incentive objects to be vested this time met the requirements.

It complies with the incentive object conditions stipulated in the "Administrative Measures", "Listing Rules" and other laws, regulations and normative documents.

The scope of incentive objects stipulated in this incentive plan is the main qualification of the incentive objects of the company's incentive plan.

Legal and valid. The third vesting period for the first grant portion of this incentive plan and the second vesting period for the reserved grant portion The vesting conditions for the period have been fulfilled. Therefore, the remuneration committee of the board of directors agreed to this vesting list.

(No text below)

Nuocheng Jianhua Pharmaceutical Co., Ltd.

Board Compensation Committee

June 16, 2026